Literature DB >> 17226813

Aggressiveness and outcome of papillary thyroid carcinoma (PTC) versus microcarcinoma (PMC): a mono-institutional experience.

C Cappelli1, M Castellano, M Braga, E Gandossi, I Pirola, E De Martino, B Agosti, E Agabiti Rosei.   

Abstract

BACKGROUND: Papillary thyroid carcinoma (PTC) represents 70%-75% of well-differentiated thyroid cancers. Although most reports have shown that papillary thyroid microcarcinomas (PMC) follow an indolent course, a few series have demonstrated that a significant number of them are associated with extrathyroidal extension and nodal or distant metastases.
METHODS: Four hundred eighty-four patients with papillary thyroid cancer (102, PMC; 382, PTC) were enrolled in this study. The median follow-up was 102 months.
RESULTS: No difference between PTC and PMC patients was observed for age, gender, multifocality, extrathyroidal extension, and lymph nodes metastasis. The prevalence of nodal involvement developing during the follow-up period was significantly higher in PMC than PTC (58.8% vs. 38.5%, P = 0.002). An unfavorable clinical course occurred in 96 subjects (21.8%). Logistic analysis showed that the strongest association with the worst prognosis was found for age and TNM stage III (P < 0.001). Analysis also confirmed that the presence of intranodular vascularity is a predictor of unfavorable outcome (P = 0.044).
CONCLUSIONS: We suggest always performing a total thyroidectomy followed by radiometabolic therapy in papillary carcinomas independent of their size. If the choice in PMCs should be more conservative (hemithyroidectomy), we purpose to limit this procedure to the cancers without Doppler features suggesting intranodular vascular pattern. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17226813     DOI: 10.1002/jso.20746

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  31 in total

1.  Usefulness of repeated recombinant human thyrotropin-stimulated thyroglobulin test in the post-surgical follow-up of very low-risk patients with differentiated thyroid carcinoma.

Authors:  C Cappelli; M Rotondi; I Pirola; E De Martino; E Gandossi; B Agosti; E Agabiti Rosei; L Chiovato; M Castellano
Journal:  J Endocrinol Invest       Date:  2011-11-07       Impact factor: 4.256

2.  Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma.

Authors:  Ji Soo Choi; Eun-Kyung Kim; Hee Jung Moon; Jin Young Kwak
Journal:  Endocrine       Date:  2014-05-25       Impact factor: 3.633

3.  Retrospective Analysis of 255 Papillary Thyroid Carcinomas ≤2 cm: Clinicohistological Features and Prognostic Factors.

Authors:  Pedro Marques; Valeriano Leite; Maria João Bugalho
Journal:  Eur Thyroid J       Date:  2014-12-06

4.  Risk Factors for Central Neck Lymph Node Metastases in Micro- Versus Macro- Clinically Node Negative Papillary Thyroid Carcinoma.

Authors:  Luca Sessa; Celestino Pio Lombardi; Carmela De Crea; Serena Elisa Tempera; Rocco Bellantone; Marco Raffaelli
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

5.  Papillary thyroid microcarcinoma: an over-treated malignancy?

Authors:  Tracy S Wang; Paolo Goffredo; Julie Ann Sosa; Sanziana A Roman
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

6.  Extensive bone metastases as the initial symptom of papillary thyroid microcarcinoma: A case report.

Authors:  Wei Zheng; Jian Tan; Guizhi Zhang
Journal:  Exp Ther Med       Date:  2015-04-14       Impact factor: 2.447

7.  Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area.

Authors:  Celestino P Lombardi; Rocco Bellantone; Carmela De Crea; Nunzia C Paladino; Guido Fadda; Massimo Salvatori; Marco Raffaelli
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 8.  The Effectiveness of Radioactive Iodine Remnant Ablation for Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-analysis.

Authors:  Guangfu Hu; Wei Zhu; Weige Yang; Hong Wang; Lei Shen; Hongwei Zhang
Journal:  World J Surg       Date:  2016-01       Impact factor: 3.352

9.  Incidental and non-incidental thyroid microcarcinoma.

Authors:  Krzysztof Kaliszewski; Beata Wojtczak; Marta Strutyńska-Karpińska; Tadeusz Łukieńczuk; Zdzisław Forkasiewicz; Paweł Domosławski
Journal:  Oncol Lett       Date:  2016-05-30       Impact factor: 2.967

10.  BRAF(V⁶⁰⁰E) mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis.

Authors:  Yu-Jia Ma; Xiu-Ling Deng; Hui-Qing Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.